1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. News
  7. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
77.67 USD   +3.27%
06/24BTIG Adjusts DexCom's Price Target to $105 From Post-Split $135, Reiterates Buy Rating
MT
06/13Come Chill at Dexcom's ‘No Pricks Parlour' With Ed Gamble for Diabetes Awareness Week, Celebrating You!
BU
06/13DEXCOM, INC. : SPLIT: 4 of 1
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating

05/17/2022 | 08:08am EDT


© MT Newswires 2022
All news about DEXCOM, INC.
06/24BTIG Adjusts DexCom's Price Target to $105 From Post-Split $135, Reiterates Buy Rating
MT
06/13Come Chill at Dexcom's ‘No Pricks Parlour' With Ed Gamble for Diabetes Awareness ..
BU
06/13DEXCOM, INC. : SPLIT: 4 of 1
FA
06/10DEXCOM INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial St..
AQ
06/08TRANSCRIPT : DexCom, Inc. Presents at William Blair’s 42nd Annual Growth Stock Confer..
CI
06/07Morgan Stanley Adjusts Price Target for DexCom to $363 From $492, Reiterates Equalweigh..
MT
06/06INSIDER SELL : Dexcom
MT
06/02Dexcom to Showcase Expanded CGM Portfolio and Industry-leading Connectivity at 82nd Sci..
BU
05/31Wall Street pulls back after last week's rally with inflation in focus
RE
05/31Unilever, DexCom rise; Gold Fields, LivePerson fall
AQ
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Financials (USD)
Sales 2022 2 921 M - -
Net income 2022 389 M - -
Net cash 2022 486 M - -
P/E ratio 2022 79,0x
Yield 2022 -
Capitalization 30 486 M 30 486 M -
EV / Sales 2022 10,3x
EV / Sales 2023 8,24x
Nbr of Employees 6 300
Free-Float 99,5%
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 77,67 $
Average target price 120,89 $
Spread / Average Target 55,6%
EPS Revisions
Managers and Directors
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Jereme M Sylvain Chief Financial Officer & EVP-Finance
Andrew K. Balo EVP-Global Medical Affairs, Access & Evidence
Jacob S. Leach Chief Technology Officer & Executive VP
Donald M. Abbey Executive VP-IT, Quality & Regulatory Affairs
Sector and Competitors
1st jan.Capi. (M$)
DEXCOM, INC.-42.14%30 486
ABBOTT LABORATORIES-22.23%191 641
MEDTRONIC PLC-12.79%119 876
BECTON, DICKINSON AND COMPANY2.10%71 528
BAXTER INTERNATIONAL INC.-22.20%33 626
HOYA CORPORATION-30.57%31 948